Chercheur

    Maja Krajinovic , M.D.

    maja.krajinovic@umontreal.ca
    Maja Krajinovic
    Axe de recherche
    Maladies virales, immunitaires et cancers
    Thème de recherche
    Pharmacologie et pharmacogénétique
    Adresse
    CHUSJ

    Téléphone
    514 345-4931 #6259

    Fax
    514 345-4731

    Titres

    • Professeure titulaire, Départements de pédiatrie et de pharmacologie, Université de Montréal.

    Formation

    • Études postdoctorales, Centre de recherche CHU Sainte-Justine, Centre de cancérologie Charles-Bruneau, Montréal, 1995-1998.
    • Études postdoctorales, International Centre for Genetic Engineering and Biotechnology, Trieste, Italie, 1992-1994.
    • Doctorat en biologie moléculaire, Université de Belgrade, Yougoslavie, 1987-1991.
    • Maitrise en génétique médicale, Université de Belgrade, 1984-1986.
    • Stage en médecine générale et licence en médecine, 1982-1984.
    • MD, Université de Belgrade, 1977-1982.

    Intérêts de recherche

    La plupart des médicaments sont caractérisés par une variabilité pharmacocinétique et pharmacodynamique, ce qui explique la variabilité des réponses observées entre des patients exposés à des posologies standards. Une telle variabilité peut expliquer les effets défavorables des médicaments comme la toxicité ou la résistance au traitement, ce qui révèle la nécessité d’identifier les facteurs associés à la variation de la sensibilité aux médicaments. Cela permettra de développer un traitement ajusté aux individus, ayant donc une efficacité accrue chez les patients résistant au traitement et une toxicité moins forte pour les patients qui y répondent bien.

    En se basant sur l’hypothèse voulant que les polymorphismes fonctionnels des gènes contrôlant des effets des médicaments (gènes candidats) contribuent significativement à la variabilité interindividuelle dans la réponse thérapeutique, nous avons développé plusieurs études en pharmacogénétique. Les principaux buts de nos projets sont : 1) de comprendre l'influence des polymorphismes de gènes candidats sur l'issue de la maladie, sur la fonction des protéines et sur l'action des drogues; 2) d’identifier des polymorphismes qui peuvent prédire le patron de résistance/toxicité chez les patients; et 3) de fournir la connaissance nécessaire à l’établissement d’une base pour le traitement personnalisé. Le projet pharmacogénétique de leucémie lymphoblastique aiguë (LLA) comprend l’étude de plusieurs agents de chimiothérapie utilisés lors du traitement. LLA est le trouble malin le plus fréquent chez l’enfant dont le traitement, malgré une amélioration du taux de survie, est associé avec la résistance au traitement et les effets secondaires des médicaments.

    De plus, nous analysons trois classes majeures de médicaments utilisés dans le traitement de l’asthme chez l’enfant. Étant donné l'incidence et la sévérité de cette maladie chez les enfants, il est primordial de fournir un traitement pouvant à la fois améliorer la santé des patients, empêcher les complications associées à la maladie dans la vie adulte et réduire les coûts. Nous avons aussi deux projets pilotes abordant la pharmacogénétique de l’acide valproique utilisé dans le traitement de l'épilepsie généralisée idiopathique (20 % des enfants avec cette maladie ne répondent pas à ce médicament) et la pharmacogénétique du busulfan un agent alkylant utilisé dans le cadre des conditionnements prégreffes de moelle osseuse. Le busulfan présente un index thérapeutique étroit : une sous-exposition augmente le risque de non prise de greffe; une surexposition risque de provoquer des complications potentiellement fatales telles qu’une maladie véno-occlusive nécessitant un suivi thérapeutique et une adaptation de posologie.

    Nous avons également amorcé un projet de recherche complémentaire qui se base sur les nouvelles approches technologiques visant le développement d’une nouvelle génération de sondes acides nucléiques qui permettront la discrimination de cibles multiples ayant une haute identité de séquence.

    Banque de données et d’échantillons biologiques sur l’asthme pédiatrique du CHU Sainte-Justine

    Prix et distinctions

    • Chercheur national, Fonds de la recherche en santé du Québec (FRSQ), 2007-2011.
    • Chercheur-boursier senior, FRSQ, 2003-2007.
    • Chercheur-boursier junior 2, 2001-2003.
    • Bourse Relève 2000, Faculté de médecine, Université de Montréal, 2000-2001.
    • Bourse de recherche postdoctorale, Fondation Centre de cancérologie Charles-Bruneau, 1995-1998.
    • Bourse de recherche postdoctorale, Téléthon, Italie, 1993-1994.

Publications

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies - Dulucq S, Laverdière C, Sinnett D, Krajinovic M. Pharmacogenetic considerations for acute lymphoblastic leukemia therapies. Expert Opin Drug Metab Toxicol 2014; 10(5): 699-719.

Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children - Huezo-Diaz P, Uppugunduri CR, Tyagi AK, Krajinovic M, Ansari M. Pharmacogenetic aspects of drug metabolizing enzymes in busulfan based conditioning prior to allogenic hematopoietic stem cell transplantation in children. Curr Drug Metab 2014; 15(3): 251-264.

Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study - Lapeyraque AL, Kassir N, Théorêt Y, Krajinovic M, Clermont MJ, Litalien C, Phan V. Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. Pediatr Nephrol 2014; 29(6): 1081-1088.

Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation - Ansari M, Théorêt Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne M, Duval M, Krajinovic M, Bittencourt H, Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Therap Drug Monit 2014; 36(1): 93-99.

Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients - Jekic B, Lukovic L, Bunjevacki V, Milic V, Novakovic I, Damnjanovic T, Milasin J, Popovic B, Maksimovic N, Damjanov N, Radunovic G, Kovacevic L, Krajinovic M. Association of the TYMS 3G/3G genotype with poor response and GGH 354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur J Clin Pharmacol 2013; 69(3): 377-383.

RGS5 gene and therapeutic response to short acting bronchodilators in paediatric asthma patients - Labuda M, Laberge S, Brière J, Bérubé D, Krajinovic M. RGS5 gene and therapeutic response to short acting bronchodilators in paediatric asthma patients. Pediatr Pulmonol 2013; 48(10): 970-975.

Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia - Gagné V, Rousseau J, Labuda M, Sharif-Askari B, Brukner I, Laverdière C, Ceppi F, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajinovic M. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin Cancer Res 2013; 19(18): 5240-5249.

Role of NOS3 DNA variants in externalizing behavioral problems observed in childhood leukemia survivors - Marcoux S, Robaey P, Gahier A, Labuda M, Rousseau J, Sinnett D, Moghrabi A, Laverdière C, Krajinovic M. Role of NOS3 DNA variants in externalizing behavioral problems observed in childhood leukemia survivors. J Pediatr Hematol Oncol 2013; 35(4): e157-162.

The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children - Ansari M, Uppugunduri CR, Ferrari-Lacraz S, Bittencourt H, Gumy-Pause F, Chalandon Y, Tiercy JM, Schechter T, Gassas A, Doyle J, Dupuis L, Duval M, Krajinovic M, Villard J. The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children. PLoS ONE 2013; 8(8): e72141.

Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway in childhood acute lymphoblastic leukemia outcome - Sanchez R, St-Cyr J, Lalonde ME, Healy J, Richer C, Gagné V, Laverdière C, Silverman LB, Sallan SE, Neuberg D, Kutok JL, Kritikou EA, Krajinovic M, Sinnett D. Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway in childhood acute lymphoblastic leukemia outcome. Haematologica 2013; (sous presse).

Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency - Autmizguine J, Krajinovic M, Rousseau J, Théorêt Y, Litalien C, Marquis C, Tapiero B, Ovetchkine P. Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency. Pharmacogenomics 2012; 13(16): 1961-1965.

Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia - Ansari M, Sauty G, Labuda M, Gagné V, Rousseau J, Moghrabi A, Laverdière C, Sinnett D, Krajinovic M. Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. Pharmacogenomics 2012; 12(5): 386-394.

Association of dihydrofolate reductase (DHFR) – 317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis - Milic V, Jekic B, Lukovic L, Bunjevacki V, Milasin J, Novakovic I, Damnjanovic T, Popovic B, Maksimovic N, Damjanov N, Radunovic G, Pejnovic N, Krajinovic M. Association of dihydrofolate reductase (DHFR) – 317AA genotype with poor response to methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 2012; 30(2): 178-183.

Predictive factors of internalized and externalized behavioral problems in children treated for acute lymphoblastic leukemia - Marcoux S, Robaey P, Krajinovic M, Moghrabi A, Laverdière C. Predictive factors of internalized and externalized behavioral problems in children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 58(6): 971-977.

A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry - Versace F, Uppugunduri CR, Krajinovic M, Théorêt Y, Gumy-Pause F, Mangin P, Staub C, Ansari M. A novel method for quantification of sulfolane (a metabolite of busulfan) in plasma by gas chromatography-tandem mass spectrometry. Anal Bioanal Chem 2012; 404(6-7): 1831-1838.

Transcriptional regulation of CYP2C19 and its role in altered enzyme activity - Uppugunduri CR, Daali Y, Desmeules J, Dayer P, Krajinovic M, Ansari M. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity. Curr Drug Metab 2012; 13(8): 1196-1204.

Steroid responsiveness and wheezing phenotypes - Ducharme F, Krajinovic M. Steroid responsiveness and wheezing phenotypes. Paediatr Respir Rev 2011; 12(3): 170-176.

ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia - Rousseau J, Gagné V, Labuda M, Beaubois C, Sinnett D, Laverdière C, Moghrabi A, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Krajinovic M. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood 2011; 118(22): 5883-5890.

Phosphodiesterase type 4D gene polymorphism: association with the response to short-acting bronchodilators in paediatric asthma patients - Labuda M, Laberge S, Brière J, Bérubé D, Beaulieu P, Pastinen T, Krajinovic M. Phosphodiesterase type 4D gene polymorphism: association with the response to short-acting bronchodilators in paediatric asthma patients. Mediators Inflamm 2011; 2011: 301695.

Exclusion of linkage to chromosomes 14q, 2q37 and 8p21.1-q11.23 in a Serbian family with idiopathic basal ganglia calcification - Kostic V, Lukić-Ječmenica M, Novakovic I, Dobričić V, Brajković L, Krajinovic M, Klein C, Pavlović A. Exclusion of linkage to chromosomes 14q, 2q37 and 8p21.1-q11.23 in a Serbian family with idiopathic basal ganglia calcification. J Neurol 2011; 258(9): 1637-1642.

Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia - Sherborne AL, Hemminki K, Kumar R, Bartram CR, Stanulla M, Schrappe M, Petridou E, Semsei AF, Szalai C, Sinnett D, Krajinovic M, Healy J, Lanciotti M, Dufour C, Indaco S, El-Ghouroury EA, Sawangpanich R, Hongeng S, Pakakasama S, Gonzalez-Neira A, Ugarte EL, Leal VP, Espinoza JP, Kamel AM, Ebid GT, Radwan ER, Yalin S, Yalin E, Berkoz M, Simpson J, Roman E, Lightfoot T, Hosking FJ, Vijayakrishnan J, Greaves M, Houlston RS. Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia. Haematologica 2011; 96(7): 1049-1054.

Special challenges: genetic polymorphisms and therapy - Krajinovic M. Special challenges: genetic polymorphisms and therapy. Dans: Advani AS, Lazarus HM (eds). Adult acute lymphocytic leukemia: biology and treatment. Humana Press, 2010; 315-330.

Dyhidrofolate reductase gene variations in susceptibility to disease and treatment outcomes - Askari BS, Krajinovic M. Dyhidrofolate reductase gene variations in susceptibility to disease and treatment outcomes. Curr Genomics 2010; 11(8): 578-583.

Polymorphisms in glucocorticoid receptor gene and the outcome of childhood acute lymphoblastic leukemia (ALL) - Labuda M, Gahier A, Gagné V, Moghrabi A, Sinnett D, Krajinovic M. Polymorphisms in glucocorticoid receptor gene and the outcome of childhood acute lymphoblastic leukemia (ALL). Leukemia Res 2010; 34(4): 492-497.

The pharmacogenetics of imatinib - Dulucq S, Krajinovic M. The pharmacogenetics of imatinib. Genome Med 2010; 2(11): 85.doi: 10.1186/gm206.

Influence of GST gene polymorphisms on busulfan pharmacokinetics in children - Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Théorêt Y, Champagne M, Krajinovic M. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant 2010; 45(2): 261-267.

Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk - Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, Gast A, Dobbins SE, Ma Y, Sheridan E, Taylor M, Kinsey SE, Lightfoot T, Roman E, Irving JA, Allan JM, Moorman AV, Harrison CJ, Tomlinson IP, Richards S, Zimmermann M, Szalai C, Semsei AF, Erdelyi DJ, Krajinovic M, Sinnett D, Healy J, Neira AG, Kawamata N, Ogawa S, Koeffler HP, Hemminki K, Greaves M, Houlston RS. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 2010; 42(6): 492-494.

Robust hybridization-based genotyping probes for HPV 6, 11, 16 and 18 obtained via in vitro selection - Brukner I, Larose AM, Gorska-Flipot I, Krajinovic M, Labuda D. Robust hybridization-based genotyping probes for HPV 6, 11, 16 and 18 obtained via in vitro selection. J Nucleic Acids Invest 2010; 1(1): e3 (on line).

Response: MRP4 gene polymorphisms and treatment response in adult ALL - Krajinovic M, Ansari M, Sinnett D. Response: MRP4 gene polymorphisms and treatment response in adult ALL. Blood 2009; 114: 5401-5402.

Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation? - Ansari M, Krajinovic M. Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?. Pharmacogenomics 2009; 10(11): 1729-1732.

DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia - Al-Shakfa F, Dulucq S, Brukner I, Milacic I, Ansari M, Beaulieu P, Moghrabi A, Laverdière C, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajinovic M. DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res 2009; 15(22): 6931-6938.

Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia - Ansari M, Sauty G, Labuda D, Gagné V, Laverdière C, Moghrabi A, Sinnett D, Krajinovic M. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 2009; 114(7): 1383-1386.

Risk factors for valproic acid resistance in childhood absence epilepsy - Ollivier ML, Dubois M-F, Krajinovic M, Cossette P, Carmant L. Risk factors for valproic acid resistance in childhood absence epilepsy. Seizure 2009; 18(10): 690-694.

DNA variants in dihydrofolate reductase gene and outcome in childhood ALL - Dulucq S, St-Onge G, Gagné V, Ansari M, Sinnett D, Labuda D, Moghrabi A, Krajinovic M. DNA variants in dihydrofolate reductase gene and outcome in childhood ALL. Blood 2008; 111(7): 3692-3700.

MTHFD1 gene: role in disease susceptibility and pharmacogenetics - Krajinovic M. MTHFD1 gene: role in disease susceptibility and pharmacogenetics. Pharmacogenomics 2008; 9(7): 829-932.

Further insight into the markers of methotrexate resistance in childhood acute lymphoblastic leukemia patients - Krajinovic M, Brukner I, Iqbal O, Bender R, Joshi VA, John T, Tsao M-S. Further insight into the markers of methotrexate resistance in childhood acute lymphoblastic leukemia patients. Personalized Med 2008; 5: 325-329.

Pharmacogenetics of the neurodevelopmental impact of anticancer chemotherapy - Robaey P, Krajinovic M, Marcoux S, Moghrabi A. Pharmacogenetics of the neurodevelopmental impact of anticancer chemotherapy. Dev Disabil Res Rev 2008; 14(3): 211-220.

Pharmacogenomics of acute leukemia - Ansari M, Krajinovic M. Pharmacogenomics of acute leukemia. Pharmacogenomics 2008; 8(7): 817-834.

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia - Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, Molimard M, Krajinovic M, Mahon FX. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008; 112(5): 2024-2027.

Newly-isolated HPV97, related to HPV18 and 45 is frequently detected in HIV-positive men from the montreal area - Gorska-Flipot I, Sawicki J, Krajinovic M, Labuda D, Brukner I, Rouleau D, Ghattas G, Franco E, Coutlée F. Newly-isolated HPV97, related to HPV18 and 45 is frequently detected in HIV-positive men from the montreal area. Int J Cancer 2008; 122(5): 1195-1197.

Pharmacogenomics: Don't forget children - Joly Y, Sillon G, Silverstein T, Krajinovic M, Avard D. Pharmacogenomics: Don't forget children. Curr Pharmacogenomics 2008; 6: 77-84.

A protocol for the in vitro selection of specific oligonucleotide probes for high-resolution DNA typing - Brukner I, Krajinovic M, Dascal A, Labuda D. A protocol for the in vitro selection of specific oligonucleotide probes for high-resolution DNA typing. Nat Protoc 2007; 2(11): 2807-2814.

Pharmacogenomics of acute lymphoblastic leukemia - Ansari M, Krajinovic M. Pharmacogenomics of acute lymphoblastic leukemia. Pharmacogenomics 2007; 8(7): 817-834.

Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy - Ansari M, Krajinovic M. Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy. Curr Opin Pediatr 2007; 19(1): 15-22.

Hybridization assay performed at ambient temperature for typing high-risk human papillomaviruses - Brukner I, El-Ramahi R, Sawicki J, Gorska-Flipot I, Krajinovic M, Labuda D. Hybridization assay performed at ambient temperature for typing high-risk human papillomaviruses. J Clin Virol 2007; 39(2): 113-118.

[Pharmacogenomics of acute lymphoblastic leukemia] - Ansari M, St-Onge G, Krajinovic M. [Pharmacogenomics of acute lymphoblastic leukemia]. Méd Sci (Paris) 2007; 23(11): 961-967.

Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene - Garcia-Bournissen F, Moghrabi A, Krajinovic M. Therapeutic responses in childhood acute lymphoblastic leukemia (ALL) and haplotypes of gamma glutamyl hydrolase (GGH) gene. Leukemia Res 2007; 31(7): 1023-1025.

An in vitro selection scheme for oligonucleotide probes to discriminate between closely related DNA sequences - Brukner I, El-Ramahi R, Gorska-Flipot I, Krajinovic M, Labuda D. An in vitro selection scheme for oligonucleotide probes to discriminate between closely related DNA sequences. Nucleic Acids Res 2007; 35(9): e66.

Further insight into the role of NQO1 in childhood leukemia - Krajinovic M. Further insight into the role of NQO1 in childhood leukemia. Haematologica 2006; 90(11): 1445.

Challenges identifying genetic determinants of pediatric cancers - the childhood leukemia experience - Sinnett D, Labuda D, Krajinovic M. Challenges identifying genetic determinants of pediatric cancers - the childhood leukemia experience. Fam Cancer 2006; 5(1): 35-47.

Phi29-based amplification of small genomes - Brukner I, Labuda D, Krajinovic M. Phi29-based amplification of small genomes. Anal Biochem 2006; 354(1): 154-156.

Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy - Todorovic Z, Dzocic E, Novakovic I, Mickovic D, Stojanovic LJ, Nesik Z, Krajinovic M, Prostran M, Kostic V. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci 2006; 248(1-2): 56-61.

Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia - Costea I, Moghrabi A, Laverdière C, Graziani A, Krajinovic M. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 2006; 91(8): 1113-1116.

[Genetic determinants of childhood leukemia] - Sinnett D, N'Diaye N, Labuda D, Krajinovic M. [Genetic determinants of childhood leukemia]. Bull Cancer 2006; 93(9): 857-865.

Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis - Krajinovic M, Costea I, Primeau M, Dulucq S, Moghrabi A. Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J 2005; 5(6): 374-380.

Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL - Krajinovic M, Robaey P, Chiasson S, Lemieux-Blanchard E, Rouillard M, Moghrabi A. Polymorphisms of genes controlling homocysteine levels and IQ score following the treatment for childhood ALL. Pharmacogenomics 2005; 6(3): 293-302.

Self-priming arrest by modified random oligonucleotides facilitates the quality control of whole genome amplification - Brukner I, Paquin B, Belouchi M, Labuda D, Krajinovic M. Self-priming arrest by modified random oligonucleotides facilitates the quality control of whole genome amplification. Anal Biochem 2005; 339(2): 345-347.

Genetic susceptibility to childhood acute lymphoblastic leukemia - Sinnett D, Meloche C, Labuda D, Mathonnet G, Moghrabi A, Sabbagh A, Infante-Rivard C, Krajinovic M. Genetic susceptibility to childhood acute lymphoblastic leukemia. Dans: Romero RM. Trends in Leukemia Research. New York. Nova Science Publishers, Inc., 2005; 1-31.

MTHFR genetic variants: an example of gene-nutrient interaction and susceptibility to childhood acute lymphoblastic leukemia - Sinnett D, Labuda D, Krajinovic M. MTHFR genetic variants: an example of gene-nutrient interaction and susceptibility to childhood acute lymphoblastic leukemia. Blood 2005; 106(7): 2590-2591.

Pharmacogenetics of methotrexate - Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics J 2004; 5(7): 819-834.

Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia - Krajinovic M, Lamothe S, Labuda D, Lemieux-Blanchard E, Théorêt Y, Moghrabi A, Sinnett D. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 2004; 103(1): 252-257.

Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia - Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004; 4(1): 66-72.

Allele specific oligonucleotide hybridization (ASO) - Labuda D, Krajinovic M, Bourgeois S. Allele specific oligonucleotide hybridization (ASO). Dans: Fuchs F, Podda M. Encyclopaedia of Diagnostic Genomics and Proteomics, volume 2. New York. Marcel Dekker, 2004; 38-41.

Polymorphisms in genes relevant for corticosteroid response and the outcome of childhood acute lymphoblastic leukemia - Fleury I, Primeau M, Costea I, Moghrabi A, Sinnett D, Krajinovic M. Polymorphisms in genes relevant for corticosteroid response and the outcome of childhood acute lymphoblastic leukemia. Am J Pharmacogenomics 2004; 4(5): 331-341.

The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia - Costea I, Moghrabi A, Krajinovic M. The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenetics 2003; 13(9): 577-580.

Pharmacogenetics of childhood acute lymphoblastic leukemia - Krajinovic M, Labuda D, Sinnett D. Pharmacogenetics of childhood acute lymphoblastic leukemia. Curr Pharmacogenomics 2003; 1: 87-100.

Role of DNA mismatch repair genetic polymorphisms in the risk of childhood acute lymphoblastic leukaemia - Mathonnet G, Krajinovic M, Labuda D, Sinnett D. Role of DNA mismatch repair genetic polymorphisms in the risk of childhood acute lymphoblastic leukaemia. Brit J Haematol 2003; 123(1): 45-48.

Characterization of the BclI polymorphism in the glucocorticoid receptor gene - Fleury I, Beaulieu P, Primeau M, Labuda D, Sinnett D, Krajinovic M. Characterization of the BclI polymorphism in the glucocorticoid receptor gene. Clin Chem 2003; 49(9): 1528-1531.

Genetic determinants to childhood acute lymphoblastic leukemia - Sinnett D, Mathonnet G, Meloche C, Moghrabi A, Labuda D, Krajinovic M. Genetic determinants to childhood acute lymphoblastic leukemia. Dans: Pandalai SG (ed). Recent Research Developments in Haematology. India. Transworld Research Network, 2003; 135-154.

Variable continental distribution of polymorphisms in the coding regions of DNA-repair genes - Mathonnet G, Labuda D, Meloche C, Wambach T, Krajinovic M, Sinnett D. Variable continental distribution of polymorphisms in the coding regions of DNA-repair genes. J Hum Genet 2003; 48(12): 659-664.

Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia - Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002; 359(9311): 1033-1034.

Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia - Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 2002; 97(2): 230-236.

Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia - Krajinovic M, Labuda D, Mathonnet G, Labuda M, Moghrabi A, Champagne J, Sinnett D. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002; 8(3): 802-810.

Glutathione-S-Transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia - Krajinovic M, Labuda D, Sinnett D. Glutathione-S-Transferase P1 genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Pharmacogenetics 2002; 12(8): 655-658.

Parental genotypes in the risk of a complex disease - Labuda D, Krajinovic M, Sabbagh A, Infante-Rivard C, Sinnett D. Parental genotypes in the risk of a complex disease. Am J Hum Genet 2002; 71(1): 193-197.

Childhood acute lymphoblastic leukemia associated with parental alcohol consumption and polymorphisms of carcinogen-metabolizing genes - Infante-Rivard C, Krajinovic M, Labuda D, Sinnett D. Childhood acute lymphoblastic leukemia associated with parental alcohol consumption and polymorphisms of carcinogen-metabolizing genes. Epidemiology 2002; 13(3): 277-281.

Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1) and glutathione S-transferases (GSTs) - Brockstedt U, Krajinovic M, Richer C, Mathonnet G, Sinnett D, Pfau W, Labuda D. Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1) and glutathione S-transferases (GSTs). Mutat Res 2002; 516(1-2): 41-47.

Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia - Laverdière C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002; 100(10): 3832-3834.

Childhood acute lymphoblastic leukemia: genetic determinants of susceptibility and disease outcome - Krajinovic M, Labuda D, Sinnett D. Childhood acute lymphoblastic leukemia: genetic determinants of susceptibility and disease outcome. Rev Environ Health 2001; 16(4): 263-279.

Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions - Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, Lacroix A, Labuda D, Sinnett D. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer 2001; 92(2): 220-225.

Genetic polymorphisms of N-acetyltransferases 1 (NAT1) and 2 (NAT2) and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia - Krajinovic M, Richer C, Sinnett H, Labuda D, Sinnett D. Genetic polymorphisms of N-acetyltransferases 1 (NAT1) and 2 (NAT2) and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarmarkers Prev 2000; 9(6): 557-562.

Genetic susceptibility to childhood acute lymphoblastic leukemia - Sinnett D, Krajinovic M, Labuda D. Genetic susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma 2000; 38(5-6): 447-462.

Parental smoking, CYP1A1 genetic polymorphisms and childhood leukemia (Quebec, Canada) - Infante-Rivard C, Krajinovic M, Labuda D, Sinnett D. Parental smoking, CYP1A1 genetic polymorphisms and childhood leukemia (Quebec, Canada). Cancer Causes Control 2000; 11(6): 547-553.

À propos de cette page

Créée le 22 juillet 2014
Signaler ou faire une remarque

Chaque dollar compte !

Merci de votre générosité.

Ce sont les donateurs comme vous qui nous permettent d’accélérer la recherche, de guérir, à chaque année, plus d’enfants et continuer d’offrir un des meilleurs niveaux de santé au monde.

Il est également possible de donner par la poste ou de donner par téléphone au numéro sans frais

1-888-235-DONS (3667)

Nous contacter

514 345-4931

Légal

© 2006-2014 Centre de recherche du CHU Sainte-Justine.
Tous droits réservés.
Avis légaux  Confidentialité  Sécurité

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine